Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS

Highly efficient and eco-innovative probiotic food supplement for antibiotic-associated disorders prevention

Cel

Development of novel probiotic solutions for specific illnesses and health problems, ex: Obesity, Depression, Crohn or Colitis diseases.

The solutions proposed by MyBiotics will use Mycrobe TM a delivery technology to overpass the biologic barriers :gastric acid, pancreatic juice and bile salts, and deliver sufficient quantity of living probiotic directly to colonize the gastro intestinal tract were they are therapeutically efficient.

MyBiotics will design for each targeted disease a set of specific bacteria and validate their selection by using MycrobeTM as leverage to provide unreached comfort and easy variation during the selection and test of the probiotics.

The ambition is to provide pharmabiotic solutions for specific diseases and provide robust clinical results for lobbying activities with the EMA, EFSA and FDA for the regulation

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

System finansowania

SME-1 - SME instrument phase 1

Wyświetl wszystkie projekty finansowane w ramach tego programu finansowania

Zaproszenie do składania wniosków

(odnośnik otworzy się w nowym oknie) H2020-SMEInst-2014-2015

Wyświetl wszystkie projekty finansowane w ramach tego zaproszenia

Koordynator

MYBIOTICS PHARMA LTD
Wkład UE netto
€ 50 000,00
Adres
5 GOLDA MEIR BLVD, RTH FLOOR
7414001 Ness Ziona
Izrael
MŚP
Tak
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Linki
Koszt całkowity
€ 71 429,00